MYC target gene activation in chronic lymphocytic leukemia and richter transformation: links to aggressiveness and tumor microenvironment interactions

Chronic Lymphocytic Leukemia (CLL) is characterized by clinical and biological heterogeneity, with a subset of patients progressing to Richter Transformation (RT), an aggressive lymphoma. This study explores MYC target gene activation across various CLL stages and disease subgroups using bulk RNAseq and single-cell RNAseq data. Our findings reveal increased MYC activation in unmutated IGHV CLLs, trisomy 12 cases, and RT stages. In RT, MYC activation is independent of B-cell receptor signaling, correlating instead with cell cycling and TLR9 interactions, indicating alternative survival mechanisms. High MYC activation correlates with shorter time to first treatment and enhances tumor microenvironment interactions, particularly with myeloid cells. These results underscore MYC's significant role in CLL progression and RT, supporting MYC's potential as a target for stratifying CLL patients and developing therapeutic strategies.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2025-08-15
DOI
https://doi.org/10.3389/fphar.2025.1642458
Primary Topic
Chronic Lymphocytic Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

MYC target gene activation in chronic lymphocytic leukemia and richter transformation: links to aggressiveness and tumor microenvironment interactions

S. Rashmi, Maria Tsagiopoulou, M. Chatziaslani
Frontiers in Pharmacology
Chronic Lymphocytic Leukemia Research
article

MYC target gene activation in chronic lymphocytic leukemia and richter transformation: links to aggressiveness and tumor microenvironment interactions

S. Rashmi, Maria Tsagiopoulou, M. Chatziaslani
article en

Abstract

Chronic Lymphocytic Leukemia (CLL) is characterized by clinical and biological heterogeneity, with a subset of patients progressing to Richter Transformation (RT), an aggressive lymphoma. This study explores MYC target gene activation across various CLL stages and disease subgroups using bulk RNAseq and single-cell RNAseq data. Our findings reveal increased MYC activation in unmutated IGHV CLLs, trisomy 12 cases, and RT stages. In RT, MYC activation is independent of B-cell receptor signaling, correlating instead with cell cycling and TLR9 interactions, indicating alternative survival mechanisms. High MYC activation correlates with shorter time to first treatment and enhances tumor microenvironment interactions, particularly with myeloid cells. These results underscore MYC's significant role in CLL progression and RT, supporting MYC's potential as a target for stratifying CLL patients and developing therapeutic strategies.

Frontiers in PharmacologyVol. 16
International Hellenic University (GR), Aristotle University of Thessaloniki (GR), Centro Nacional de Análisis Genómico (ES), Universitat de Barcelona (ES)
Generalitat de Catalunya, Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III, European Regional Development Fund
Openalex Percentile: Top 71%
Chronic Lymphocytic Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

MYC target gene activation in chronic lymphocytic leukemia and richter transformation: links to aggressiveness and tumor microenvironment interactions — S. Rashmi, Maria Tsagiopoulou, et al. · Frontiers in Pharmacology (2025) | TGRS Research Map | TGRS